1-8 of 8
A. Douglas Laird
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Shunsuke Kimura, Lindsey Montefiori, Ilaria Iacobucci, Yaqi Zhao, Qingsong Gao, Elisabeth M. Paietta, Claudia Haferlach, A. Douglas Laird, Paul E. Mead, Zhaohui Gu, Wendy Stock, Mark Litzow, Jacob M. Rowe, Selina M. Luger, Stephen P. Hunger, Georgina L. Ryland, Breon Schmidt, Paul G. Ekert, Alicia Oshlack, Sean M. Grimmond, Jacqueline Rehn, James Breen, David Yeung, Deborah L. White, Ibrahim Aldoss, Elias J. Jabbour, Ching-Hon Pui, Manja Meggendorfer, Wencke Walter, Wolfgang Kern, Torsten Haferlach, Samuel Brady, Jinghui Zhang, Kathryn G. Roberts, Piers Blombery, Charles G. Mullighan
Journal: Blood
Blood (2022) 139 (24): 3519–3531.
https://doi.org/10.1182/blood.2022015444
Published: 2022
Includes: Supplemental data
Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1344.
https://doi.org/10.1182/blood-2019-122097
Published: 2019
Journal Articles

Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, Katherine F Liau, Kevin Nguyen, Barbara Sleight, Erik Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, Anjali S. Advani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2699.
https://doi.org/10.1182/blood-2018-99-110826
Published: 2018
Journal Articles

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Partow Kebriaei, MD, Daniel J. DeAngelo, MD, Anjali S. Advani, MD, Susan M. O'Brien, MD, David Marks, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Tao Wang, Erik Vandendries, MD PhD, A. Douglas Laird, PhD, Sonja Nick, MSc, Matthias Stelljes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4031.
https://doi.org/10.1182/blood-2018-99-110552
Published: 2018
Journal Articles

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, MD, Wendy Stock, MD, Michaela Liedtke, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Jane Liang White, ScD, Tao Wang, PhD, A. Douglas Laird, PhD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2557.
https://doi.org/10.1182/blood.V130.Suppl_1.2557.2557
Published: 2017
Journal Articles

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, PhD, Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, MD PhD, A. Douglas Laird, Anjali S. Advani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1272.
https://doi.org/10.1182/blood.V130.Suppl_1.1272.1272
Published: 2017
Journal Articles

Exploring Relationships of Exposure, Pharmacodynamic Changes and Gene Expression to Clinical Outcome in Adults with Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin

Luke Fostvedt, A. Douglas Laird, Jean-Claude Marshall, Sherry Li, Joseph P. Boni, PhD BS
Journal: Blood
Blood (2015) 126 (23): 3698.
https://doi.org/10.1182/blood.V126.23.3698.3698
Published: 2015
Journal Articles

Complete remission of TEL-PDGFRB –induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657

Brief Report
Jennifer A. Cain, Jay L. Grisolano, A. Douglas Laird, Michael H. Tomasson
Journal: Blood
Blood (2004) 104 (2): 561–564.
https://doi.org/10.1182/blood-2003-11-3801
Published: 2004